Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBIT (2023 - 2025)

Camp4 Therapeutics' EBIT history spans 3 years, with the latest figure at -$12.8 million for Q4 2025.

  • For Q4 2025, EBIT rose 8.97% year-over-year to -$12.8 million; the TTM value through Dec 2025 reached -$52.6 million, up 1.0%, while the annual FY2025 figure was -$52.6 million, 1.0% up from the prior year.
  • EBIT for Q4 2025 was -$12.8 million at Camp4 Therapeutics, up from -$13.7 million in the prior quarter.
  • Across five years, EBIT topped out at -$12.7 million in Q2 2024 and bottomed at -$14.0 million in Q4 2024.
  • The 3-year median for EBIT is -$13.1 million (2025), against an average of -$13.2 million.
  • The largest annual shift saw EBIT fell 4.15% in 2024 before it increased 8.97% in 2025.
  • A 3-year view of EBIT shows it stood at -$13.5 million in 2023, then decreased by 4.15% to -$14.0 million in 2024, then grew by 8.97% to -$12.8 million in 2025.
  • Per Business Quant, the three most recent readings for CAMP's EBIT are -$12.8 million (Q4 2025), -$13.7 million (Q3 2025), and -$13.0 million (Q2 2025).